Dalian

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Stroke3 trials
• Familial hypercholesterolaemia2 trials
• Chronic spontaneous urticaria1 trial
• Immune thrombocytopenia (ITP)1 trial
• Metastatic breast cancer1 trial
• Myeloproliferative neoplasms1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Active, not recruiting5 trials
• Completed2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals9 trials

Running trials

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

  NCT05653349· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

  NCT04544189· Phase 2· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms1 recruiting

Closed trials

• Completed

  A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China

  NCT06053801· Novartis Pharmaceuticals· Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source